In a significant advancement for infant health, two new studies have confirmed the safety and efficacy of prenatal RSV vaccination and infant monoclonal antibodies in protecting babies from respiratory syncytial virus (RSV) during their first six months of life. Conducted at the UCSF Birth Center from October 2023 to April 2024, the studies revealed that a combination of these preventive measures safeguarded approximately 80% of infants during the 2023-24 RSV season. The research included nearly 2,000 pregnant individuals and newborns, providing a robust analysis of the vaccine's safety and effectiveness.
The analysis focused on about 650 mothers, with 260 infants whose mothers did not receive the prenatal vaccination but were eligible for monoclonal antibody treatment. The study underscored the potential of these interventions in reducing severe RSV complications, which annually result in 80,000 hospitalizations among children under the age of five and account for 3.6% of infant deaths globally in the age group of 28 days to six months.
Dr. Christine Blauvelt, a co-author of the study, emphasized the vaccine’s safety, stating:
“Prenatal RSV vaccination and infant monoclonal antibodies against RSV are safe and effective ways to protect babies against RSV during the first 6 months of life when they are most vulnerable to this disease,” – Blauvelt
Despite the promising results, the study revealed a need for increased vaccination rates. Only around 21% of pregnant individuals received the vaccine, while 35% of babies benefitted from monoclonal antibodies. Supply issues may have influenced these numbers early in the study period. However, in California, many mothers who declined the prenatal vaccine opted for monoclonal antibody treatments instead.
Dr. Blauvelt highlighted the logistical challenges and the potential solutions:
“Having the RSV vaccine available in prenatal clinics and nirsevimab available on labor and delivery units may reduce logistical barriers to vaccination,” – Blauvelt
Another key point from the research is that a high uptake rate of both preventive measures could lead to RSV herd immunity. In fact, about 64% of pregnant individuals were vaccinated before childbirth, and 70% of eligible newborns received nirsevimab, a specific monoclonal antibody treatment. This strengthens the case for widespread adoption of these interventions as effective public health strategies.
Dr. Yonekura Collier pointed out the broader implications by referencing successful outcomes in Spain:
“In locations in Spain where they achieved nearly 90% nirsevimab rates, there is substantial real-world effectiveness data for RSV prevention,” – Collier
The UCSF study’s timing also had an impact on its findings. Dr. Collier noted:
“Had we looked only at October 15 to January 1, my guess is our numbers would have been largely similar,” – Yonekura Collier
Leave a Reply